Business
Theralase Announces Pricing Of Prospectus Offering
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITE...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Theralase Announces Pricing Of Prospectus OfferingNOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESTORONTO, ON / ACCESSWIRE / August 1, 2019 / Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers, is pleased to announce today the price of its marketed public offering previously announced on June 26, 2019 (the “Offering”). The Offering will be conducted at a price of $0.30 per unit of the Company (a “Unit”) for minimum gross proceeds of $7,500,000 and maximum gross proceeds of $15,000,000 (the “Offering”). Each Unit will be comprised of one common share of the Company (the “Common Shares”) and one common share purchase warrant (the “Warrants”). Each Warrant shall be exercisable to acquire one Common Share at a price of $0.35, for a period of 60 months from the closing of the Offering.The Offering is being led by Mackie Research Capital Corporation as the lead agent and sole bookrunner (the “Lead Agent”), on behalf of a syndicate, including Maxim Group LLC, a United States registered broker-dealer, as sub-agent for any sales of the Units in the United States only (together, the “Agents”). The Offering is being undertaken on a commercially reasonable “best efforts” agency basis in all provinces of Canada, except Québec, pursuant to the Company’s preliminary short form prospectus dated June 25, 2019 (the “Preliminary Prospectus”) filed, and pursuant to a final short form prospectus to be filed with securities regulators in each of the provinces of Canada, except Québec (collectively, the “Prospectus”). The Units may also be offered on a private placement basis pursuant to an exemption from the registration requirements of the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) and applicable state securities laws, as well as other jurisdictions outside of Canada and the United States as the Company and Lead Agen...